-
Categories
-
Pharmaceutical Intermediates
-
Active Pharmaceutical Ingredients
-
Food Additives
- Industrial Coatings
- Agrochemicals
- Dyes and Pigments
- Surfactant
- Flavors and Fragrances
- Chemical Reagents
- Catalyst and Auxiliary
- Natural Products
- Inorganic Chemistry
-
Organic Chemistry
-
Biochemical Engineering
- Analytical Chemistry
-
Cosmetic Ingredient
- Water Treatment Chemical
-
Pharmaceutical Intermediates
Promotion
ECHEMI Mall
Wholesale
Weekly Price
Exhibition
News
-
Trade Service
[Pharmaceutical Network Market Analysis] In the context of the specialized division of labor in the global pharmaceutical industry, the market size of the pharmaceutical CDMO industry has achieved rapid grow.
According to data forecast, in 2022, the scale of China's pharmaceutical CDMO market may reach 59 billion yuan, and the global pharmaceutical CDMO industry market scale will reach 106 billion US dolla.
By 2025, the market size of the global pharmaceutical CDMO industry may reach US$106 billi.
According to statistics, the market size of the global pharmaceutical CDMO industry has grown from US$33 billion in 2016 to US$54 billion in 2020, with a compound annual growth rate of nearly 1
It is estimated that from 2020 to 2025, the compound annual growth rate of the global pharmaceutical CDMO industry market will reach 1
The global pharmaceutical CDMO market is expected to reach US$73 billion in 2022, and is expected to reach US$106 billion by 202Looking at the domestic market, the size of the pharmaceutical CDMO market has grown from 15 billion yuan in 2016 to 37 billion yuan in 2020, with an average annual compound growth rate of 38
It is predicted that the scale of China's pharmaceutical CDMO market will reach 59 billion yuan in 2022, of which the chemical drug and biological drug CDMO market scale may reach 39 billion yuan and 19 billion yuan respective.
By 2025, the size of China's CDMO market is expected to reach 125 billion yu.
From 2020 to 2025, the five-year compound growth rate is about 3
The CDMO industry mainly serves the innovative drugs of multinational pharmaceutical companies and emerging R&D companies, and has high requirements in terms of technical level, management ability, and intellectual property protecti.
In recent years, China's pharmaceutical CDMO comprehensive technology level and comprehensive management system have been continuously improved, and the company's performance has also performed we.
Among them, according to the performance forecast recently released by CDMO enterprise Proton, it is expected that the company will achieve a net profit of 191 billion yuan to 212 billion yuan in the first half of 2022, a year-on-year increase of 455%-46
Regarding performance growth, Proton shares disclosed in its semi-annual report that the company continued to promote the CDMO strategy, and continued to expand and enrich customer pipelines and product pipelines; with the successful delivery of major orders received in the previous period, it is expected to achieve operating income of 83 billion yuan -956 billion yuan, a year-on-year increase of 205%-21
In the first half of 2022, Jiuzhou Pharmaceutical will also continue to expand the layout of the CDMO business sector, always adhere to customer demand-oriented, deeply expand customer pipelines and product pipelines, steadily improve the company's R&D capabilities and product delivery capabilities, and further realize the CDMO busine.
quality increa.
In the first half of 2022, the net profit attributable to shareholders of listed companies is expected to be 45481 million yuan to 489647 million yuan, an increase of 65% to 75% year-on-ye.
Baicheng Pharmaceutical also stated on the investor interaction platform recently that with the construction and investment of the company's CDMO base, the company's CDMO business has a good development tre.
The CDMO industry is maintaining a good development tre.
Analysts pointed out that from the perspective of the CXO (pharmaceutical outsourcing) segment, the performance growth rate of small molecule CDMOs (contract R&D and production organizations) in 2022 will be relatively high.
On the one hand, based on the order structure of each company, the advancement of existing projects in the early stage brings strong performance certainty; on the other hand, some orders for blockbuster small molecule new drugs will bring greater performance to the industry and related compani.
Incremental growth, while amplifying the spillover effect of industry orders in the short te.
The future of China's small molecule CDMO industry is promisi.
In the pharmaceutical field, CDMO as a branch is playing an increasingly important ro.
CDMO carries the function of specialized production in the pharmaceutical indust.
At present, the global CDMO industry is in the golden age of a new wave of pharmaceutical research and developme.
With the vigorous development of the CDMO market and the iterative expansion of market demand, innovative service companies with high-tech development and optimization capabilities and vertical extension of the industrial chain may win the futu.
Disclaimer: Under no circumstances does the information or opinions expressed in this article constitute investment advice to anyo.
According to data forecast, in 2022, the scale of China's pharmaceutical CDMO market may reach 59 billion yuan, and the global pharmaceutical CDMO industry market scale will reach 106 billion US dolla.
By 2025, the market size of the global pharmaceutical CDMO industry may reach US$106 billi.
According to statistics, the market size of the global pharmaceutical CDMO industry has grown from US$33 billion in 2016 to US$54 billion in 2020, with a compound annual growth rate of nearly 1
It is estimated that from 2020 to 2025, the compound annual growth rate of the global pharmaceutical CDMO industry market will reach 1
The global pharmaceutical CDMO market is expected to reach US$73 billion in 2022, and is expected to reach US$106 billion by 202Looking at the domestic market, the size of the pharmaceutical CDMO market has grown from 15 billion yuan in 2016 to 37 billion yuan in 2020, with an average annual compound growth rate of 38
It is predicted that the scale of China's pharmaceutical CDMO market will reach 59 billion yuan in 2022, of which the chemical drug and biological drug CDMO market scale may reach 39 billion yuan and 19 billion yuan respective.
By 2025, the size of China's CDMO market is expected to reach 125 billion yu.
From 2020 to 2025, the five-year compound growth rate is about 3
The CDMO industry mainly serves the innovative drugs of multinational pharmaceutical companies and emerging R&D companies, and has high requirements in terms of technical level, management ability, and intellectual property protecti.
In recent years, China's pharmaceutical CDMO comprehensive technology level and comprehensive management system have been continuously improved, and the company's performance has also performed we.
Among them, according to the performance forecast recently released by CDMO enterprise Proton, it is expected that the company will achieve a net profit of 191 billion yuan to 212 billion yuan in the first half of 2022, a year-on-year increase of 455%-46
Regarding performance growth, Proton shares disclosed in its semi-annual report that the company continued to promote the CDMO strategy, and continued to expand and enrich customer pipelines and product pipelines; with the successful delivery of major orders received in the previous period, it is expected to achieve operating income of 83 billion yuan -956 billion yuan, a year-on-year increase of 205%-21
In the first half of 2022, Jiuzhou Pharmaceutical will also continue to expand the layout of the CDMO business sector, always adhere to customer demand-oriented, deeply expand customer pipelines and product pipelines, steadily improve the company's R&D capabilities and product delivery capabilities, and further realize the CDMO busine.
quality increa.
In the first half of 2022, the net profit attributable to shareholders of listed companies is expected to be 45481 million yuan to 489647 million yuan, an increase of 65% to 75% year-on-ye.
Baicheng Pharmaceutical also stated on the investor interaction platform recently that with the construction and investment of the company's CDMO base, the company's CDMO business has a good development tre.
The CDMO industry is maintaining a good development tre.
Analysts pointed out that from the perspective of the CXO (pharmaceutical outsourcing) segment, the performance growth rate of small molecule CDMOs (contract R&D and production organizations) in 2022 will be relatively high.
On the one hand, based on the order structure of each company, the advancement of existing projects in the early stage brings strong performance certainty; on the other hand, some orders for blockbuster small molecule new drugs will bring greater performance to the industry and related compani.
Incremental growth, while amplifying the spillover effect of industry orders in the short te.
The future of China's small molecule CDMO industry is promisi.
In the pharmaceutical field, CDMO as a branch is playing an increasingly important ro.
CDMO carries the function of specialized production in the pharmaceutical indust.
At present, the global CDMO industry is in the golden age of a new wave of pharmaceutical research and developme.
With the vigorous development of the CDMO market and the iterative expansion of market demand, innovative service companies with high-tech development and optimization capabilities and vertical extension of the industrial chain may win the futu.
Disclaimer: Under no circumstances does the information or opinions expressed in this article constitute investment advice to anyo.
